文献速递免疫规划

视黄酸预处理下调霍乱弧菌外膜囊泡诱导的急性炎症并增强黏膜免疫

Retinoic acid pre-treatment down regulates V. cholerae outer membrane vesicles induced acute inflammation and enhances mucosal immunity.
PubMed 文献 · Vaccine · 2017-05-22

本研究聚焦在保持霍乱五价外膜囊泡(CPMVs)抗原性的同时降低其毒性,选用全反式视黄酸(ATRA)进行预处理。结果显示,ATRA预处理在体外和体内均显著降低CPMVs诱导的TLR2介导的促炎反应,并在两剂口服免疫(75µg CPMVs)后显著诱导黏膜免疫应答和保护效力。

要点

  • ATRA预处理在体外和体内均显著降低CPMVs诱导的TLR2介导的促炎反应。
  • 两剂口服免疫(75µg CPMVs)后,ATRA预处理显著诱导黏膜免疫应答和保护效力。
  • 该研究有助于降低基于OMV疫苗的毒性并诱导更好的保护性免疫。

核心结论

  • ATRA预处理可降低CPMVs诱导的TLR2介导的促炎反应,并在两剂口服免疫后显著诱导黏膜免疫应答和保护效力。

研究设计与样本

  • 本研究在小鼠模型中探讨ATRA预处理对CPMVs免疫原性的影响,包括体外和体内实验。

主要发现

  • ATRA预处理在体外和体内均显著降低CPMVs诱导的TLR2介导的促炎反应。
  • 两剂口服免疫(75µg CPMVs)后,ATRA预处理显著诱导黏膜免疫应答和保护效力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bacterial outer membrane vesicles have been extensively investigated and considered as a next generation vaccine. Recently, we have demonstrated that the cholera pentavalent outer membrane vesicles (CPMVs) immunogen induced adaptive immunity and had a strong protective efficacy against the circulating V. cholerae strains in a mouse model. In this present study, we are mainly focusing on reducing outer membrane vesicle (OMV) -mediated toxicity without altering its antigenic property. Therefore, we have selected All-trans Retinoic Acid (ATRA), active metabolites of vitamin A, which have both anti-inflammatory and mucosal adjuvant properties. Pre-treatment of ATRA significantly reduced CPMVs induced TLR2 mediated pro-inflammatory responses in vitro and in vivo. Furthermore, we also found ATRA pre-treatment significantly induced mucosal immune response and protective efficacy after two doses of oral immunization with CPMVs (75µg). This study can help to reduce OMV based vaccine toxicity and induce better protective immunity where children and men suffered from malnutrition mainly in developing countries.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sinha R, Howlader DR, Ta A, et al. Retinoic acid pre-treatment down regulates V. cholerae outer membrane vesicles induced acute inflammation and enhances mucosal immunity. Vaccine. 2017. PMID: 28545924. doi:10.1016/j.vaccine.2017.05.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。